Overview

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Status:
Terminated
Trial end date:
1998-02-02
Target enrollment:
Participant gender:
Summary
Current therapies for Stage IV non-small cell lung cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV lung cancer PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute